CG
JAZZ icon

Caprock Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Caprock Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.49M Buy
7,880
+286
+4% +$50K 0.04% 435
2025
Q4 		$1.29M Buy
+7,594
New +$1.16M 0.03% 535
2025
Q1 		– Sell
-1,674
Closed -$206K – 1130
2024
Q4 		$206K Buy
+1,674
New +$197K 0.01% 931

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Caprock Group's JAZZ Position: Q1 2026 in Review

Caprock Group increased its Jazz Pharmaceuticals (JAZZ) stake by 3.8% in Q1 2026, buying an estimated $50K and bringing the position to 7,880 shares worth $1.49M. The position accounts for 0.04% of the portfolio, ranked #435.

Caprock Group first reported a position in JAZZ in Q4 2024 and has held it in 3 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Caprock Group held 7,880 shares of Jazz Pharmaceuticals worth $1.49M as of Q1 2026.
  • Caprock Group bought 286 Jazz Pharmaceuticals shares in Q1 2026, an estimated $50K.
  • Jazz Pharmaceuticals made up 0.04% of Caprock Group's portfolio in Q1 2026, its #435 holding.
  • Caprock Group first reported a position in Jazz Pharmaceuticals in Q4 2024 and has held it in 3 quarters since.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Caprock Group's 13F filing for Q1 2026, filed 11 May 2026.